RET Fusion-Positive Lung Adenocarcinoma: Partner-Specific Clinicopathological Characteristics, Co-Mutation Profiles, and Implications for Targeted and Immunotherapy.

Abstract excerpt

BACKGROUND: RET fusions represent actionable oncogenic drivers in lung adenocarcinoma (LUAD). However, the clinicopathological features, co-mutation landscape, and therapeutic outcomes across different fusion partners remain incompletely characterized. METHODS: We retrospectively analyzed 268 patients with RET fusion-positive LUAD diagnosed between July 2017 and December 2024. Clinicopathological features,...

Topics

Join the communities discussing this publication.

• Adenocarcinoma of Lung
• Biomarkers, Tumor
• Immunotherapy
• Lung Neoplasms
• Molecular Targeted Therapy